Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Vincristine Sulfate

FDA-approved product (injectable, injection), marketed as Marqibo Kit, Oncovin, Vincasar Pfs and 3 more.

Registered studies
50+
Lab records
0
Pathogens at ≥40%
3 of 4

Chemical structure

Chemical structure of Vincristine Sulfate
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Neoplasm

Indications ChEMBL records as approved, from FDA and DailyMed labels.

WHO therapeutic group
Vinca alkaloids and analogues
Anti-infective classification
Not classified as an anti-infective.

Repurposing investigation

This medicine is being investigated here for AI-predicted antimicrobial activity against E. coli, MRSA and M. tuberculosis. It was surfaced computationally for further investigation; it is not an established treatment for these infections.

AI-predicted activity

AI prediction · nothing measured
  • MRSA59.0% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli47.2% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae36.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis67.6% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

No evidence found

No laboratory measurement against the four pathogens in the ChEMBL records loaded here.

Open Vincristine Sulfate in ChEMBL Registered studies below

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

Not yet docked: queued in the docking rundetails

KPC-2 carbapenemase ↗ (K. pneumoniae)

Not yet docked: queued in the docking rundetails

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

Not yet docked: queued in the docking rundetails

Dihydrofolate reductase ↗ (MRSA)

Not yet docked: queued in the docking rundetails

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Vincristine Sulfate with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • Combination Chemotherapy and Rituximab in Treating Patients With Primary Mediastinal Diffuse Large B-Cell Lymphoma

    NCT00689845 · start 2007-06

    Registered record
    Registry ID
    NCT00689845
    Conditions
    Lymphoma
    Interventions
    bleomycin sulfate; filgrastim; rituximab; cyclophosphamide; cytarabine; doxorubicin hydrochloride; etoposide phosphate; ifosfamide; methotrexate; prednisolone; prednisone; vincristine sulfate; vindesine
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Unknown
    Start
    2007-06
    Completion
    Not recorded
    Enrolment
    120

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma
    Interventionbleomycin sulfate; filgrastim; rituximab; cyclophosphamide +9 more
    PhaseNot applicable
    Registry statusUnknown

  • A Study of Participants With Lymphoma Who Take R-CHOP and Enzastaurin Compared to Participants Who Take R-CHOP Only

    NCT00451178 · start 2007-05

    Registered record
    Registry ID
    NCT00451178
    Conditions
    Lymphoma
    Interventions
    enzastaurin; rituximab; cyclophosphamide; doxorubicin; vincristine; prednisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2007-05
    Completion
    2013-01
    Enrolment
    101

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma
    Interventionenzastaurin; rituximab; cyclophosphamide; doxorubicin +2 more
    PhasePhase 2
    Registry statusCompleted

  • Treating Young Patients With Newly Diagnosed, Low Stage, Lymphocyte Predominant Hodgkin Disease

    NCT00107198 · start 2006-03-10

    Registered record
    Registry ID
    NCT00107198
    Conditions
    Ann Arbor Stage I Childhood Hodgkin Lymphoma; Ann Arbor Stage II Childhood Hodgkin Lymphoma; Childhood Nodular Lymphocyte Predominant B-Cell Lymphoma
    Interventions
    Conventional Surgery; Cyclophosphamide; Doxorubicin Hydrochloride; Prednisone; Radiation Therapy; Vincristine Sulfate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-03-10
    Completion
    2026-03-31
    Enrolment
    188

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAnn Arbor Stage I Childhood Hodgkin Lymphoma; Ann Arbor Stage II Childhood Hodgkin Lymphoma; Childhood Nodular Lymphocyte Predominant B-Cell Lymphoma
    InterventionConventional Surgery; Cyclophosphamide; Doxorubicin Hydrochloride; Prednisone +2 more
    PhasePhase 2
    Registry statusCompleted

  • GEM05 for Patients With Multiple Myeloma Under 65 Years

    NCT00461747 · start 2006-03

    Registered record
    Registry ID
    NCT00461747
    Conditions
    Multiple Myeloma
    Interventions
    VBMCP/VBAD/Velcade; Thalidomide/Dexamethasone; Velcade/Thalidomide/Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-03
    Completion
    2008-12
    Enrolment
    390

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma
    InterventionVBMCP/VBAD/Velcade; Thalidomide/Dexamethasone; Velcade/Thalidomide/Dexamethasone
    PhasePhase 3
    Registry statusCompleted

  • Imatinib Mesylate and Combination Chemotherapy With or Without a Donor Stem Cell Transplant in Treating Patients With Newly Diagnosed Acute Lymphoblastic Leukemia

    NCT00618501 · start 2005-10

    Registered record
    Registry ID
    NCT00618501
    Conditions
    Leukemia
    Interventions
    cytarabine; daunorubicin hydrochloride; etoposide; imatinib mesylate; leucovorin calcium; methotrexate; prednisolone; therapeutic hydrocortisone; vincristine sulfate; allogeneic hematopoietic stem cell transplantation
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-10
    Completion
    2009-01
    Enrolment
    50

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia
    Interventioncytarabine; daunorubicin hydrochloride; etoposide; imatinib mesylate +6 more
    PhasePhase 2
    Registry statusCompleted

  • Study of Rituximab-HCVAD Alternating With Rituximab-Methotrexate-Cytarabine Versus Standard Rituximab-CHOP Every 21 Days for Patients With Newly Diagnosed High Risk Aggressive B-Cell Non-Hodgkin's Lymphomas in Patients 60 Years Old or Younger

    NCT00290498 · start 2005-08-01

    Registered record
    Registry ID
    NCT00290498
    Conditions
    Lymphoma
    Interventions
    Rituximab; Cyclophosphamide; Doxorubicin; Vincristine; Dexamethasone; Methotrexate; Cytarabine; Prednisone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2005-08-01
    Completion
    2017-08-11
    Enrolment
    67

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma
    InterventionRituximab; Cyclophosphamide; Doxorubicin; Vincristine +4 more
    PhasePhase 2
    Registry statusCompleted

  • Study: Treatment of Relapsed Lymphoid Malignancies With an Anti-Angiogenic Approach

    NCT00250718 · start 2004-10

    Registered record
    Registry ID
    NCT00250718
    Conditions
    Non-Hodgkin's Lymphoma; Cancer
    Interventions
    Vincristine; VP-16; Rituximab; Dexamethasone; Levofloxacin
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Terminated
    Start
    2004-10
    Completion
    2014-05
    Enrolment
    17

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionNon-Hodgkin's Lymphoma; Cancer
    InterventionVincristine; VP-16; Rituximab; Dexamethasone +1 more
    PhasePhase 2
    Registry statusTerminated

  • Chemotherapy With or Without Imatinib and/or Peripheral Stem Cell Transplant in Acute Lymphoblastic Leukemia

    NCT00458848 · start 2004-10

    Registered record
    Registry ID
    NCT00458848
    Conditions
    Leukemia
    Interventions
    asparaginase; daunorubicin hydrochloride; etoposide; idarubicin; imatinib mesylate; mercaptopurine; methotrexate; methylprednisolone; mitoxantrone hydrochloride; prednisone; vincristine sulfate; allogeneic hematopoietic stem cell transplantation; autologous hematopoietic stem cell transplantation; peripheral blood stem cell transplantation; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-10
    Completion
    2014-03
    Enrolment
    470

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia
    Interventionasparaginase; daunorubicin hydrochloride; etoposide; idarubicin +11 more
    PhasePhase 2
    Registry statusCompleted

  • Combination Chemotherapy and Thalidomide in Treating Patients With Stage I, Stage II, or Stage III Multiple Myeloma

    NCT00054158 · start 2004-08

    Registered record
    Registry ID
    NCT00054158
    Conditions
    Multiple Myeloma and Plasma Cell Neoplasm
    Interventions
    dexamethasone; doxorubicin hydrochloride; thalidomide; vincristine sulfate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2004-08
    Completion
    Not recorded
    Enrolment
    24

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMultiple Myeloma and Plasma Cell Neoplasm
    Interventiondexamethasone; doxorubicin hydrochloride; thalidomide; vincristine sulfate
    PhasePhase 2
    Registry statusCompleted

  • Combination Chemotherapy and Cyclosporine Followed by Focal Therapy for Bilateral Retinoblastoma

    NCT00110110 · start 2004-06

    Registered record
    Registry ID
    NCT00110110
    Conditions
    Retinoblastoma
    Interventions
    filgrastim; Carboplatin; Cyclosporine; Etoposide; vincristine sulfate; cryosurgery; laser therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Unknown
    Start
    2004-06
    Completion
    2024-12-31
    Enrolment
    71

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionRetinoblastoma
    Interventionfilgrastim; Carboplatin; Cyclosporine; Etoposide +3 more
    PhasePhase 2
    Registry statusUnknown

  • Combination Chemotherapy and Radiation Therapy in Treating Young Patients With Hodgkin's Lymphoma

    NCT00416832 · start 2002-11

    Registered record
    Registry ID
    NCT00416832
    Conditions
    Lymphoma
    Interventions
    cyclophosphamide; dacarbazine; doxorubicin hydrochloride; etoposide; prednisone; procarbazine hydrochloride; vincristine sulfate; radiation therapy
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-11
    Completion
    2005-12
    Enrolment
    648

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma
    Interventioncyclophosphamide; dacarbazine; doxorubicin hydrochloride; etoposide +4 more
    PhasePhase 2
    Registry statusCompleted

  • Study of Imatinib-Combined Chemotherapy for BCR-ABL-Positive Acute Lymphoblastic Leukemia (ALL)

    NCT00130195 · start 2002-09

    Registered record
    Registry ID
    NCT00130195
    Conditions
    Acute Lymphoblastic Leukemia
    Interventions
    imatinib; cyclophosphamide; daunorubicin; vincristine; prednisolone; methotrexate; cytarabine; dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-09
    Completion
    2008-05
    Enrolment
    100

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcute Lymphoblastic Leukemia
    Interventionimatinib; cyclophosphamide; daunorubicin; vincristine +4 more
    PhasePhase 2
    Registry statusCompleted

  • Rituximab and Hyper-CVAD (Cyclophosphamide, Vincristine, Adriamycin, and Dexamethasone) for Burkitt's and Burkitt's -Like Leukemia/Lymphoma

    NCT00669877 · start 2002-08

    Registered record
    Registry ID
    NCT00669877
    Conditions
    Burkitt's Lymphoma; Burkitt'S-like Lymphoma
    Interventions
    Rituximab; Cyclophosphamide; Doxorubicin; Vincristine; Dexamethasone; G-CSF; Cytarabine; Methotrexate
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2002-08
    Completion
    2015-10
    Enrolment
    56

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionBurkitt's Lymphoma; Burkitt'S-like Lymphoma
    InterventionRituximab; Cyclophosphamide; Doxorubicin; Vincristine +4 more
    PhasePhase 2
    Registry statusCompleted

  • Safety and Efficacy Study of Iodine-131 Anti-B1 Antibody Plus CHOP For Untreated Mantle Cell Lymphoma

    NCT00992992 · start 2001-06-28

    Registered record
    Registry ID
    NCT00992992
    Conditions
    Lymphoma, Mantle-Cell
    Interventions
    Tositumomab and Iodine I 131 Tositumomab followed by CHOP
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2001-06-28
    Completion
    2013-06-30
    Enrolment
    25

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLymphoma, Mantle-Cell
    InterventionTositumomab and Iodine I 131 Tositumomab followed by CHOP
    PhasePhase 2
    Registry statusCompleted

  • TITLE:Less Intensive Therapy for Children With Non-Hodgkin's Lymphoma

    NCT00002757 · start 2001-06

    Registered record
    Registry ID
    NCT00002757
    Conditions
    Leukemia; Lymphoma
    Interventions
    filgrastim; cyclophosphamide; cytarabine; doxorubicin hydrochloride; etoposide; methotrexate; prednisolone; prednisone; therapeutic hydrocortisone; vincristine sulfate
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2001-06
    Completion
    2009-10
    Enrolment
    1,148

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionLeukemia; Lymphoma
    Interventionfilgrastim; cyclophosphamide; cytarabine; doxorubicin hydrochloride +6 more
    PhasePhase 3
    Registry statusCompleted